- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic rhinosinusitis with nasal polyps
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 1.2MB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 292KB)
Mepolizumab – November 2022
Mepolizumab: Injection 100 mg in 1 mL single dose pre-filled pen; Nucala®
Last updated
3 March 2023